These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18055864)

  • 1. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.
    Oki Y; Jelinek J; Shen L; Kantarjian HM; Issa JP
    Blood; 2008 Feb; 111(4):2382-4. PubMed ID: 18055864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.
    Braun T; Itzykson R; Renneville A; de Renzis B; Dreyfus F; Laribi K; Bouabdallah K; Vey N; Toma A; Recher C; Royer B; Joly B; Vekhoff A; Lafon I; Sanhes L; Meurice G; Oréar C; Preudhomme C; Gardin C; Ades L; Fontenay M; Fenaux P; Droin N; Solary E;
    Blood; 2011 Oct; 118(14):3824-31. PubMed ID: 21828134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP
    Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia.
    Subari S; Patnaik M; Alfakara D; Zblewski D; Hook C; Hashmi S; Hogan W; Litzow M; Al-Kali A
    Leuk Lymphoma; 2016 Jul; 57(7):1714-5. PubMed ID: 26462118
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.
    Merlevede J; Droin N; Qin T; Meldi K; Yoshida K; Morabito M; Chautard E; Auboeuf D; Fenaux P; Braun T; Itzykson R; de Botton S; Quesnel B; Commes T; Jourdan E; Vainchenker W; Bernard O; Pata-Merci N; Solier S; Gayevskiy V; Dinger ME; Cowley MJ; Selimoglu-Buet D; Meyer V; Artiguenave F; Deleuze JF; Preudhomme C; Stratton MR; Alexandrov LB; Padron E; Ogawa S; Koscielny S; Figueroa M; Solary E
    Nat Commun; 2016 Feb; 7():10767. PubMed ID: 26908133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.
    Meldi K; Qin T; Buchi F; Droin N; Sotzen J; Micol JB; Selimoglu-Buet D; Masala E; Allione B; Gioia D; Poloni A; Lunghi M; Solary E; Abdel-Wahab O; Santini V; Figueroa ME
    J Clin Invest; 2015 May; 125(5):1857-72. PubMed ID: 25822018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
    Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
    Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
    Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
    Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.
    Yi JH; Huh J; Kim HJ; Kim SH; Kim SH; Kim KH; Do YR; Mun YC; Kim H; Kim MK; Kim HJ; Kim T; Kim DD
    Ann Hematol; 2013 Apr; 92(4):459-69. PubMed ID: 23262795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of two chronic myelomonocytic leukemia patients with Decitabine].
    Wang L; Wang HX; Zhao J
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):497. PubMed ID: 22213878
    [No Abstract]   [Full Text] [Related]  

  • 11. Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.
    Iastrebner M; Jang JH; Nucifora E; Kim K; Sackmann F; Kim DH; Orlando S; Jung CW; Basquiera A; Klein G; Santini F; Bernard HI; Korin J; Taborda G
    Leuk Lymphoma; 2010 Dec; 51(12):2250-7. PubMed ID: 20929328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decitabine--bedside to bench.
    Oki Y; Aoki E; Issa JP
    Crit Rev Oncol Hematol; 2007 Feb; 61(2):140-52. PubMed ID: 17023173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
    Lübbert M; Wijermans P; Kunzmann R; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
    Br J Haematol; 2001 Aug; 114(2):349-57. PubMed ID: 11529854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical update on hypomethylating agents.
    Duchmann M; Itzykson R
    Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
    Berg JL; Perfler B; Hatzl S; Mayer MC; Wurm S; Uhl B; Reinisch A; Klymiuk I; Tierling S; Pregartner G; Bachmaier G; Berghold A; Geissler K; Pichler M; Hoefler G; Strobl H; Wölfler A; Sill H; Zebisch A
    Clin Epigenetics; 2021 Jan; 13(1):1. PubMed ID: 33407852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy.
    Steensma DP; Friday BB
    Leuk Lymphoma; 2007 Aug; 48(8):1628-9. PubMed ID: 17701595
    [No Abstract]   [Full Text] [Related]  

  • 17. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
    Duchmann M; Braun T; Micol JB; Platzbecker U; Park S; Pilorge S; Beyne-Rauzy O; Vey N; Sébert M; Gruson B; Dumas PY; Guieze R; Chretien ML; Laribi K; Chait Y; Legros L; Sahnes L; Hirsch P; Salanoubat C; Solary E; Fenaux P; Itzykson R
    Blood Cancer J; 2017 May; 7(5):e562. PubMed ID: 28498370
    [No Abstract]   [Full Text] [Related]  

  • 18. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
    Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
    Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rare case of acquired haemophilia in a patient with chronic myelomonocytic leukaemia successfully treated with decitabine.
    Shah D; Kumar R; Gaikazian S
    Haemophilia; 2014 Jan; 20(1):e92-4. PubMed ID: 24261579
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
    Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
    Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.